The prevalence of atrial fibrillation is much greater among persons with end-stage renal disease (ESRD) than among the general population. While significant advances have been made recently in the treatment of atrial fibrillation in the general population, we know very little about the treatment of atrial fibrillation among those with ESRD. This Commentary explores gaps in our knowledge of how to treat this vulnerable and sick population.
Atrial fi brillation is far more common in patients with end-stage renal disease (ESRD) than in the general population. However, estimates of its prevalence vary widely in the literature. Th is Commentary addresses the relevance of methods of defining atrial fibrillation in ESRD patients, and the numerous unaddressed questions on how to treat atrial fi brillation in this population.
Th e prevalence of atrial fi brillation in the general public rises with age from 0.4 -1.0 % overall to approximately 8 % in people in their ninth decade of life. 1 Prior estimates of the prevalence of atrial fi brillation among end-stage renal disease (ESRD) patients, however, dwarf the frequency in the general population, but they have varied widely, ranging from 10.9 to 27 % depending on the population studied. 2 -5 Further, mortality among people with ESRD and atrial fibrillation is increased almost twofold from the already high rates for those with ESRD but without atrial fibrillation. 5 Given the more than 1.5 million people with ESRD internationally, a thorough understanding of the burden of atrial fibrillation in our patients with ESRD is essential for understanding the magnitude of the gaps in evidence-based treatment. 6 Wetmore et al. 7 (this issue) present an estimate of the prevalence of atrial fi brillation in a novel database of US patients eligible for both Medicare and Medicaid. Using billing claims, they identified patients with atrial fi brillation and estimated its prevalence at 7.0 % , with a tight range (95 % confi dence interval 6.8 -7.2 % ) given the size of the data set ( > 63,000 people). Th e strength of this estimate is based on the rigorous way in which people with atrial fi brillation were identifi ed, focusing on its clinical relevance. For a patient to be categorized as having atrial fi brillation, the diagnosis had to appear in at least two billing claims separated by more than 30 days, at least one of which had to be outpatient. Th is estimate of prevalence, although lower than the previously reported range, should not discount the burden of disease, as we can now state that atrial fi brillation is as common overall in the entire population of people with ESRD as it is in the group with the highest burden (those in their 80 s) in the general population.
In light of this tremendous burden of disease, what do we know about its treatment in people with ESRD ( Figure 1 )? We know that the risk -benefi t ratio of anticoagulation in patients with ESRD and atrial fi brillation is not the same as that among those with normal kidney function. No randomized trials have been done. However, an observational cohort study of more than 48,000 ESRD patients examined the 1671 patients with documented atrial fi brillation. 8 Of those, 508 received warfarin, 43 received clopidogrel, 304 received aspirin, 336 received two or more of these treatments, and 480 received no anticoagulation or antiplatelet treatment for the prevention of stroke. Because this was an observational study, comparison of outcomes among groups is limited by the indication bias associated with the therapy chosen. Patients receiving warfarin were more likely to be male and less likely to have comorbidities such as diabetes, coronary artery disease, and prior history of stroke. However, with those biases in mind, the highest rate of new strokes was seen among those receiving warfarin (7.1 per 100 person-years at risk), followed by those receiving aspirin, no treatment, and clopidogrel (3.5, 2.9, and 2.7 per 100 person-years at risk, respectively). Although observational data can establish only association, not cause and eff ect, these data strongly support the conclusion that warfarin may not be the best treatment for people with ESRD and atrial fi brillation. Given the small numbers of patients receiving antiplatelet therapy, it is not possible to address whether these agents provide a reduction in stroke risk.
New therapeutic options for the prevention of stroke in atrial fi brillation include the oral factor Xa inhibitors apixaban and rivaroxaban. 9, 10 Both demonstrated noninferiority when compared with warfarin, with trends toward superiority, but neither study enrolled sufficient numbers of patients with severe kidney disease or ESRD to examine their effi cacy in these populations. Given that both agents saw a decrement in the rate of hemorrhagic stroke and bleeding episodes as compared with the control arm receiving warfarin, the potential exists for a therapeutic benefi t among those with ESRD. However, in that these drugs are partially cleared by the kidneys, dedicated trials are of paramount importance.
From the studies published in the traditionally renal literature, one would conclude that the only relevant clinical questions for patients with ESRD are prevalence and the choice as to whether or not to anticoagulate. However, a plethora of even more essential questions remain to be addressed among people with atrial fi brillation and kidney disease.
Th e newly updated guidelines on the treatment of atrial fi brillation 11 highlight the results of two recently published trials assessing how to approach rate control. Th e RACE II (Rate Control Effi cacy in Permanent Atrial Fibrillation) trial randomized patients with atrial fi brillation to strict control (resting heart rate < 80 beats per minute) vs. lenient control (resting heart rate < 110 beats per minute) and observed the effect on cardiovascular death, heart failure hospitalization, stroke, systemic embolism, bleeding, and lifethreatening arrhythmias. 12 Over the 3-year follow up, one of these cardiovascular events was seen in 12.9 % of the lenientcontrol group and 14.9 % of the strictcontrol group. Additionally, the Atrial Fibrillation and Congestive Heart Failure Trial was completed, randomizing subjects to rhythm control using amiodarone and cardioversion as compared with rate control using beta-blockers and digitalis. 13 No diff erences were seen between groups with respect to death, heart failure, or stroke, but the group randomized to rhythm control was more likely to require hospitalization during the course of the trial.
Th e ability to extrapolate these somewhat counterintuitive results to patients with kidney disease is again, however, limited. Th e diff erences in blood vessel compliance as measured by pulse pressure 13 and the complexity of the associations between hemodynamic changes on dialysis and mortality 14 in comparison with people with normal kidney function may modify the eff ect of whether rhythm control is achieved and of to what extent rate control is maintained. Given that an estimated 20 % of ventricular fi lling occurs due to the ' atrial kick ' and that cardiac output is directly related to stroke volume, the question of how important adequate ventricular fi lling is during times of cardiovascular stress such as hemodialysis with 4 l of ultrafi ltration may have a diff erent answer in someone with ESRD.
Finally, future directions in the treatment of atrial fibrillation include catheter-based oblation for symptomatic paroxysmal atrial fibrillation that has failed one or more drugs. In the Th ermoCool trial, recurrence of symptomatic atrial fi brillation occurred in 34 % of the group receiving oblation during the 9 months of follow-up as compared with 84 % of those receiving medications for rate of rhythm control. 15 There are no data for patients with ESRD. But given the real lack of data on safety for any of the agents recommended for use in rate and rhythm control (amiodarone, dofetilide, dronedarone, propafenone, sotalol, and fl ecainide) and the risk associated with anticoagulation, perhaps this will be the most therapeutic option.
Whether we are estimating that 7 % of 500,000 or 7 % of 1.5 million have atrial fi brillation in the United States or worldwide, the paucity of data on treatment is remarkable. Given the huge burden demonstrated with the conservative and specifi c criteria used by Wetmore et al. , 7 there is defi nitely justifi cation (if there was not before) to conduct trials to truly understand and treat this dangerous comorbidity.
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